Navigation Links
Jane Moffitt, J.D., LL.M. Named Vice President of Regulatory Affairs of Nile Therapeutics

BERKELEY, Calif., May 8 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused on developing therapies for cardiovascular disease, is pleased to announce the appointment of Jane Moffitt, J.D., LL.M. as its Vice President of Regulatory Affairs.

"We believe Jane's specific leadership contribution to the launch and development of natriuretic peptide BNP, Natrecor(R), plus her extensive regulatory affairs background will be of great value to Nile as we develop our own natriuretic peptide, CD-NP and cardiovascular pipeline," said Peter Strumph, Chief Executive Officer of Nile.

Ms. Moffitt has over 30 years of professional experience in regulatory affairs and corporate and food & drug law for pharmaceutical, device and biotechnology companies. This experience includes developing clinical regulatory strategies and leading teams responsible for preparing and maintaining INDs, NDAs, BLAs and global product launches. Her drug product expertise includes natriuretic peptides, small molecules and biologics.

Prior to joining Nile, Ms. Moffitt was the West Coast Director of Operations for SciLucent, a specialty healthcare-focused consulting firm. Prior to that, Jane was a Senior Vice President of Quality and Regulatory Affairs at a number of pharmaceutical and medical device companies, including Revance Therapeutics Inc., Scios, Inc., Collagen Corporation, and Amsco International Inc., and worked as a corporate attorney at Miles Laboratories, Inc. At Scios, Ms. Moffitt was a member of the Corporate Management Committee, started the Government Affairs function and was the head of the regulatory affairs function. Ms. Moffitt also served as President, Treasurer and a member of the Board of Directors of Scios R&D, Inc. and BRP, Inc.

Ms Moffitt holds a B.S. in Biology and Political Science from Dickinson College, a J.D. from Dickinson School of Law and a LL.M. in Trade Regulation from New York University School of Law.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric natriuretic peptide in clinical studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Isilon Named Best of Show at Bio-IT World 2008
2. Flashpoint Medica Named Agency of Year by Medical Advertising News
3. Highmark Inc. Named an Age-Friendly Employer by
4. Boston Scientific Named Healthcare Supplier of the Year by Global Healthcare Exchange (GHX)
5. Trenita Ward Named Vice President, California Member Service Call Centers for Kaiser Permanente
6. WeissComm Partners Named Healthcare Agency of the Year
7. Mental Health Prescription Program Named Winner in URACs Best Practices in Consumer Empowerment and Protection Awards
8. Doug Burcin and Donna Murphy Named Advertising Persons of the Year
9. Jenni Schaefer, Motivational Speaker, Author Named National Eating Disorders Association (NEDA) Ambassador
10. Laura Loughridge Wargo Named Chief Development Officer for American Red Cross - Southeastern Michigan Chapter
11. Agito Networks Named Finalist for Red Herring North America 100 Award out of More Than 800 Companies
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
Breaking Medicine Technology: